D-myo-inositol 1,4,5-trisphosphate analogues modified at the 3-position inhibit phosphatidylinositol 3-kinase.
Several natural and unnatural inositol phosphates and analogues were analyzed for their ability to inhibit the in vitro phosphatidylinositol 3-kinase (PI 3-kinase) activity immunoprecipitated from a leukemic T cell line by a p85 monoclonal antibody. A 3-position ring-modified analogue of D-myo-inositol 1,4,5-trisphosphate (Ins(1,4,5)P3), L-chiro-inositol 2,3,5-trisphosphate (L-chiro-Ins(2,3,5)P3) and its phosphorothioate analogue, L-chiro-inositol 2,3,5-trisphosphorothioate, as well as the analogue benzene 1,2,4-trisphosphate induced reversible inhibition of PI 3-kinase activity, which correlated with decreased Vmax but unchanged Km values for PI 3-kinase. Other inositol phosphates, including D- and L-Ins(1,4,5)P3, D-myo-inositol 1,3,4,5-tetrakisphosphate, the enantiomers of myo-inositol 1,3,4-trisphosphate, DL-myo-inositol 1,4,6-trisphosphate (DL-Ins(1,4,6)P3), and DL-scyllo-inositol 1,2,4-trisphosphate (DL-scyllo-Ins(1,2,4)P3), did not inhibit PI 3-kinase activity under identical conditions. L-chiro-Ins(2,3,5)P3 closely resembles Ins(1,4,5)P3 and D-Ins(1,4,6)P3 except for a difference in the orientation of a single hydroxyl group at either the equivalent 3-OH or 2-OH position of Ins(1,4,5)P3, respectively. Similarly, L-chiro-Ins(2,3,5)P3 resembles D-scyllo-Ins(1,2,4)P3, but has a different orientation of both the equivalent 3-OH and 2-OH positions. Since Ins(1,4,5)P3, DL-Ins(1,4,6)P3, and DL-scyllo-Ins(1,2,4)P3 did not inhibit PI 3-kinase activity, this suggests that the orientation of the two hydroxyl groups at the 2- and 3-positions plays a pivotal role in the inhibitory action of inositol phosphate analogues on PI 3-kinase activity. Thus, inositol phosphate analogues inter alia are shown for the first time to inhibit PI 3-kinase and may be useful tools for determining the function of PI 3-kinase and its substrate binding specificities.
Ward
S G
SG
School of Pharmacy and Pharmacology, University of Bath, Avon, United Kingdom.
Mills
S J
SJ
Liu
C
C
Westwick
J
J
Potter
B V
BV
D002236:Carbohydrate Conformation; D015195:Drug Design; D015544:Inositol 1,4,5-Trisphosphate / Q000031:analogs & derivatives* / Q000138:chemical synthesis / Q000494:pharmacology; D007700:Kinetics; D015459:Leukemia-Lymphoma, Adult T-Cell; D015394:Molecular Structure; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors; D019869:Phosphatidylinositol 3-Kinases; D017853:Phosphotransferases (Alcohol Group Acceptor) / Q000037:antagonists & inhibitors*; D013329:Structure-Activity Relationship; D014407:Tumor Cells, Cultured
D009363:Neoplasm Proteins; D015544:Inositol 1,4,5-Trisphosphate; D019869:Phosphatidylinositol 3-Kinases; D017853:Phosphotransferases (Alcohol Group Acceptor)